Inlyta Evrópusambandið - íslenska - EMA (European Medicines Agency)

inlyta

pfizer europe ma eeig  - axitinib - krabbamein, nýrnafrumur - prótín nt-hemlar - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Qinlock Evrópusambandið - íslenska - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinal stromal tumors - Æxlishemjandi lyf - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Duta Tamsaxiro Hart hylki 0,5/0,4 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

duta tamsaxiro hart hylki 0,5/0,4 mg

medical valley invest ab - dutasteridum inn; tamsulosinum hýdróklóríð - hart hylki - 0,5/0,4 mg

Zokinvy Evrópusambandið - íslenska - EMA (European Medicines Agency)

zokinvy

eigerbio europe limited - lonafarnib - progeria; laminopathies - Önnur meltingarvegi og efnaskipti vörur, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

Duodart Hart hylki 0,5/0,4 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

duodart hart hylki 0,5/0,4 mg

glaxosmithkline pharma a/s - dutasteridum inn; tamsulosinum hýdróklóríð - hart hylki - 0,5/0,4 mg

Abilify Maintena Evrópusambandið - íslenska - EMA (European Medicines Agency)

abilify maintena

otsuka pharmaceutical netherlands b.v. - aripíprazól - geðklofa - psycholeptics - viðhald meðferð geðklofa í fullorðinn sjúklingar stöðug með inntöku sjúklingum.

Imbruvica Evrópusambandið - íslenska - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Odomzo Evrópusambandið - íslenska - EMA (European Medicines Agency)

odomzo

sun pharmaceutical industries europe b.v. - sonidegib tvífosfat - krabbamein, basalfrumur - Æxlishemjandi lyf - odomzo er ætlað til meðferðar hjá fullorðnum sjúklingum með staðbundið langt gengið grunnfrumukrabbamein (bcc) sem ekki er hægt að lækna með skurðaðgerð eða geislameðferð.

Xtandi Evrópusambandið - íslenska - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.